Natural and structure-based RXR Ligand scaffolds and their functions

Current Topics in Medicinal Chemistry

Volumn 17, Issue 6, 2017, Pages 631-662

  Dominguez, Marta ^a   Alvarez, Susana ^a   de Lera, Angel R ^a  

^a UNIVERSITY OF VIGO   (Spain)

Author keywords

Agonists; Antagonists; Heterodimers; Ligands; Natural products; Rexinoid scaffolds; Rexinoids; RXR

Indexed keywords

13,14 DIHYDRORETINOIC ACID; CARBOXYLIC ACID; DANTRON; DOCOSAHEXAENOIC ACID; ICOSANOID; PERETINOIN; PHYTANIC ACID; RETINOIC ACID; RETINOID X RECEPTOR; RETINOL DEHYDROGENASE; UNCLASSIFIED DRUG; LIGAND;

ADIPOGENESIS; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; MASS SPECTROMETRY; MOLECULAR MODEL; PROTEIN EXPRESSION; REVIEW; TRANSIENT TRANSFECTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; CHEMISTRY; HUMAN; PHYSIOLOGY; PROTEIN CONFORMATION;

ANIMALS; HUMANS; LIGANDS; PROTEIN CONFORMATION; RETINOID X RECEPTORS;

EID: 85011072182     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160617072521     Document Type: Review

References (200)

1. Laudet, V.; Gronemeyer, H. The Nuclear Receptor Facts Book. Academic Press: San Diego, 2002.
2. Germain, P.; Chambon, P.; Eichele, G.; Evans, R. M.; Lazar, M. A.; Leid, M.; de Lera, A. R.; Lotan, R.; Mangelsdorf, D. J.; Gronemeyer, H. The pharmacology and classification of the nuclear receptor superfamily. Retinoid x Receptors (RXRs). Pharmacol. Rev., 2006, 58, 760-772.
3. Gronemeyer, H.; Gustafsson, J.-A.; Laudet, V. Principles for Modulation of the Nuclear Receptor Superfamily. Nat. Rev. Drug Disc., 2004, 3, 950-964.
4. Huang, P.; Chandra, V.; Rastinejad, F. Retinoic Acid Actions through Mammalian Nuclear Receptors. Chem. Rev., 2014, 114, 233-254.
5. Mangelsdorf, D. A.; Evans, R. M. The RXR Heterodimers and Orphan Receptors. Cell, 1995, 83, 841-850.
6. Hermanson, O.; Glass, C. K.; Rosenfeld, M. G. Nuclear Receptor Coregulators: multiple modes of modifications. Trends Endocrinol. Metab., 2002, 13, 55-60.
7. Jepsen, K.; Hermanson, O.; Onami, T. M.; Gleiberman, A. S.; Lunyak, V.; McEvilly, R. J.; Kurokawa, R.; Kumar, V.; Liu, F.; Seto, E.; Hedrick, S. M.; Mandel, G.; Glass, C. K.; Rose, D. W.; Rosenfeld, M. G. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell, 2000, 102, 753-63.
8. Smith, C. L.; O'Malley, B. W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev., 2004, 25, 45-71.
9. Evans, R. M.; Mangelsdorf, D. J. Nuclear Receptors, RXR, and the Big Bang. Cell, 2014, 157, 255-266.
10. Germain, P.; Iyer, J.; Zechel, C.; Gronemeyer, H. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature, 2002, 415, 187-192.
11. Altucci, L.; Leibowitz, M. D.; Ogilvie, K. M.; de Lera, A. R.; Gronemeyer, H. RAR and RXR Modulation in Cancer and Metabolic Disease. Nat. Rev. Drug Disc., 2007, 6, 793-810.
12. Kersten, S.; Kelleher, D.; Chambon, P.; Gronemeyer, H.; Noy, N. Retinoid X receptor a forms tetramers in solution. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 8645-8649.
13. Kersten, S.; Pan, L.; Chambon, P.; Gronemeyer, H.; Noy, N. Role of Ligand in Retinoid Signalling. 9-cis-Retinoic Acid Modulates the Oligomeric State of the Retinoid X Receptor. Biochemistry, 1995, 34, 13717-13721.
14. Kersten, S.; Pan, L.; Noy, N. On the Role of Ligand in Retinoid Signalling: Positive Cooperativity in the Interactions of 9-cis-Retinoic Acid with Tetramers of the Retinoid X Receptor. Biochemistry, 1995, 34, 14263-14269.
15. Zhang, H.; Chen, L.; Chen, J.; Jiang, H.; Shen, X. Structural Basis for Retinoic X Receptor Repression on the Tetramer. J. Biol. Chem., 2011, 286, 24593-24598.
16. Egea, P. F.; Mitschler, A.; Rochel, N.; Ruff, M.; Chambon, P.; Moras, D. Crystal structure of the human RXRa ligand-binding domain bound to its natural ligand: 9-cis-retinoic acid. EMBO J., 2000, 19, 2592-2601.
17. Egea, P. F.; Mitschler, A.; Moras, D. Molecular Recognition of Agonist Ligands by RXRs. Mol. Endocrinol., 2002, 16, 987-997.
18. Bourguet, W.; Vivat, V.; Wurtz, J.-M.; Chambon, P.; Gronemeyer, H.; Moras, D. Crystal Structure of a Heterodimeric Complex of RAR and RXR Ligand-Binding Domains. Mol. Cell, 2000, 5, 289-298.
19. Svensson, S.; Ostberg, T.; Jacobsson, M.; Norstrom, C.; Stefansson, K.; Hallen, D.; Johansson, I. C.; Zachrisson, K.; Ogg, D.; Jendeberg, L. Crystal structure of the heterodimeric complex of LXRa and RXRb ligand-binding domains in a fully agonistic conformation. EMBO J., 2003, 22, 4625-4633.
20. Sato, Y.; Ramalanjaona, N.; Huet, T.; Potier, N.; Osz, J.; Antony, P.; Peluso-Iltis, C.; Poussin-Courmontagne, P.; Ennifar, E.; Mely, Y.; Dejaegere, A.; Moras, D.; Rochel, N. The "Phantom Effect" of the Rexinoid LG100754: Structural and Functional Insights. PLoS ONE, 2010, 5, e15119.
21. Germain, P.; Gaudon, C.; Pogenberg, V.; Sanglier, S.; Potier, N.; Van Dorsselaer, A.; Royer, C. A.; Lazar, M. A.; Bourguet, W.; Gronemeyer, H. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem. Biol., 2009, 16, 479-489.
22. le Maire, A.; Teyssier, C.; Erb, C.; Grimaldi, M.; Alvarez, S.; de Lera, A. R.; Balaguer, P.; Gronemeyer, H.; Royer, C. A.; Germain, P.; Bourguet, W. A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor. Nat. Struct. Mol. Biol., 2010, 17, 801-807.
23. Bourguet, W.; de Lera, A. R.; Gronemeyer, H. Inverse Agonists and Antagonists of Retinoid Receptors. In Meth. Enzymol., Conn, P. M., Ed. Academic Press: New York, 2010; Vol. 485, pp. 161-195.
24. Perez, E.; Bourguet, W.; Gronemeyer, H.; de Lera, A. R. Modulation of RXR function through ligand design. Biochim. Biophys. Acta (BBA) -Mol. Cell Biol. Lip., 2012, 1821, 57-69.
25. le Maire, A.; Alvarez, S.; Shankaranarayanan, P.; de Lera, A. R.; Bourguet, W.; Gronemeyer, H. Retinoid receptors and therapeutic applications of RAR/RXR modulators. Curr. Top. Med. Chem., 2012, 12, 505-527.
26. Kagechika, H. Novel Synthetic Retinoids and Separation of the Pleiotropic Retinoidal Activities. Curr. Med. Chem., 2002, 9, 591-680.
27. Kagechika, H.; Shudo, K. Synthetic Retinoids: Recent Developments Concerning Structure and Clinical Utility. J. Med. Chem., 2005, 48, 5875-5883.
28. de Lera, A. R.; Bourguet, W.; Altucci, L.; Gronemeyer, H. Design of Selective Nuclear Receptor Modulators: RAR and RXR as a Case Study. Nature Rev. Drug. Disc., 2007, 6, 811-820.
29. Barnard, J. H.; Collings, J. C.; Whiting, A.; Przyborski, S. A.; Marder, T. B. Synthetic Retinoids: Structure–Activity Relationships. Chem. Eur. J., 2009, 15, 11430-11442.
30. Alvarez, S.; Bourguet, W.; Gronemeyer, H.; de Lera, A. R. Retinoic acid receptor modulators: a perspective on recent advances and promises. Expert Opin. Ther. Patents, 2011, 21, 55-63.
31. Vaz, B.; de Lera, A. R. Advances in drug design with RXR modulators. Exp. Op. Drug Disc., 2012, 7, 1003-1016.
32. Dawson, M. I.; Xia, Z. The retinoid X receptors and their ligands. Biochem. Biophys. Acta-Mol. Cell Biol. Lip., 2012, 1821, 21-56.
33. Dawson, M. I.; Zhang, X.-k. Discovery and Design of Retinoic Acid Receptor and Retinoid X Receptor Class-and Subtype-Selective Synthetic Analogs of All-trans-retinoic Acid and 9-cis-Retinoic Acid. Curr. Med. Chem., 2002, 9, 623-637.
34. Dawson, M. I. Synthetic Retinoids and Their Nuclear Receptors. Curr. Med. Chem.-Anti-Cancer Agents, 2004, 4, 199-230.
35. Alvarez, R.; Vaz, B.; Gronemeyer, H.; de Lera, A. R. Functions, therapeutic applications, and synthesis of retinoids and carotenoids. Chem. Rev., 2014, 114, 1-125.
36. Wolf, G. Is 9-Cis-Retinoic Acid the Endogenous Ligand for the Retinoic Acid-X Receptor? Nutr. Rev., 2006, 64, 532-538.
37. Kojima, R.; Fujimori, T.; Kiyota, N.; Toriya, Y.; Fukuda, T.; Ohashi, T.; Sato, T.; Yoshizawa, Y.; Takeyama, K.; Mano, H.; Masushige, S.; Kato, S. In Vivo Isomerization of Retinoic Acids. J. Biol. Chem., 1994, 269, 32700-32707.
38. (a) Heyman, R. A.; Mangelsdorf, D. J.; Dyck, J. A.; Stein, R. B.; Eichele, G.; Evans, R. M.; Thaller, C. 9-Cis-retinoic acid is a high affinity ligand for the retinoid X receptor. Cell, 1992, 68, 397-406
39. (b) Levin, A. A.; Sturzenbecker, L. J.; Kazmer, S.; Bosakowski, T.; Huselton, C.; Allenby, G.; Speck, J.; ratzeisen, C.; Rosenberger, M.; Lovey, A.; Grippo, J. F. Nature, 1992, 355, 359-361.
40. Pappas, R. S.; Newcomer, M. E.; Ong, D. E. Endogenous retinoids in rat epididymal tissue and rat and human spermatozoa. Biol. Reprod., 1993, 48, 235-247.
41. Kane, M. A.; Folias, A. E.; Pingitore, A.; Perri, M.; Obrochta, K. M.; Krois, C. R.; Cione, E.; Ryu, J. Y.; Napoli, J. L. Identification of 9-cis-retinoic acid as a pancreas-specific autacoid that attenuates glucose-stimulated insulin secretion. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 21884-21889.
42. Kane, M. A. Analysis, occurrence, and function of 9-cis-retinoic acid. Biochim. Biophys. Acta (BBA) -Mol. Cell Biol. Lip., 2012, 1821, 10-20.
43. Arnold, S. L. M.; Amory, J. K.; Walsh, T. J.; Isoherranen, N. A sensitive and specific method for measurement of multiple retinoids in human serum with UHPLC-MS/MS. J. Lipid Res., 2012, 53, 587-598.
44. Costaridis, P.; Horton, C.; Zeitlinger, J.; Holder, N.; Maden, M. Endogenous retinoids in the zebrafish embryo and adult. Dev. Dyn., 1996, 205, 41-51.
45. Ulven, S. M.; Gundersen, T. E.; Sakhi, A. K.; Glover, J. C.; Blomhoff, R. Quantitative axial profiles of retinoic acid in the embryonic mouse spinal cord: 9-cis-retinoic acid only detected after all-trans-retinoic acid levels are super-elevated experimentally. Dev. Dyn., 2001, 222, 341-353.
46. Schmidt, C. K.; Brouwer, A.; Nau, H. Chromatographic analysis of endogenous retinoids in tissues and serum. Anal. Biochem., 2003, 315, 36-48.
47. Yamakoshi, Y.; Fukasawa, H.; Yamauchi, T.; Waki, H.; Kadowaki, T.; Shudo, K.; Kagechika, H. Determination of Endogenous Levels of Retinoic Acid Isomers in Type II Diabetes Mellitus Patients. Possible Correlation with HbA1c Values. Biol. Pharm. Bull., 2002, 25, 1268-1271.
48. Werner, E. A.; DeLuca, H. F. Metabolism of a Physiological Amount of all-trans-Retinol in the Vitamin A-Deficient Rat. Arch. Biochem. Biophys., 2001, 393, 262-270.
49. Ruhl, R. Method to determine 4-oxo-retinoic acids, retinoic acids and retinol in serum and cell extracts by liquid chromatography/ diode-array detection atmospheric pressure chemical ionisation tandem mass spectrometry. Rapid Commun. Mass Spectrom., 2006, 20, 2497-2504.
50. Gundersen, T. E.; Bastani, N. E.; Blomhoff, R. Quantitative highthroughput determination of endogenous retinoids in human plasma using triple-stage liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom., 2007, 21, 1176-1186.
51. Wongsiriroj, N.; Jiang, H.; Piantedosi, R.; Yang, K. J. Z.; Kluwe, J.; Schwabe, R. F.; Ginsberg, H.; Goldberg, I. J.; Blaner, W. S. Genetic dissection of retinoid esterification and accumulation in the liver and adipose tissue. J. Lipid Res., 2014, 55, 104-114.
52. Tryggvason, K.; Romert, A.; Eriksson, U. Biosynthesis of 9-cisretinoic acid in vivo: the roles of different retinol dehydrogenases and a structure-activity analysis of microsomal retinol dehydrogenases. J. Biol. Chem., 2001, 276, 19253-19258.
53. Calleja, C.; Messaddeq, N.; Chapellier, B.; Yang, H.; Krezel, W.; Li, M.; Metzger, D.; Mascrez, B.; Ohta, K.; Kagechika, H.; Endo, Y.; Mark, M.; Ghyselinck, N. B.; Chambon, P. Genetic and pharmacological evidence that a retinoic acid cannot be the RXRactivating ligand in mouse epidermis keratinocytes. Genes Dev., 2006, 20, 1525-1538.
54. Mic, F. A.; Molotkov, A.; Benbrook, D. M.; Duester, G. Retinoid Activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 7135-7140.
55. Ziouzenkova, O.; Orasanu, G.; Sharlach, M.; Akiyama, T. E.; Berger, J. P.; Viereck, J.; Hamilton, J. A.; Tang, G.; Dolnikowski, G. G.; Vogel, S.; Duester, G.; Plutzky, J. Retinaldehyde represses adipogenesis and diet-induced obesity. Nat. Med., 2007, 13, 695-702.
56. Moise, A. R.; Alvarez, S.; Dominguez, M.; Alvarez, R.; Golczak, M.; Lobo, G. P.; von Lintig, J.; de Lera, A. R.; Palczewski, K. Activation of Retinoic Acid Receptors by Dihydroretinoids. Mol. Pharmacol., 2009, 76, 1228-1237.
57. Moise, A. R.; Kuksa, V.; Imanishi, Y.; Palczewski, K. Identification of all-trans-retinol : all-trans-13,14-dihydroretinol saturase. J. Biol. Chem., 2004, 279, 50230-50242.
58. Moise, A. R.; Kuksa, V.; Blaner, W. S.; Baehr, W.; Palczewski, K. Metabolism and Transactivation Activity of 13,14-Dihydroretinoic Acid. J. Biol. Chem., 2005, 280, 27815-27825.
59. Moise, A. R.; Dominguez, M.; Alvarez, S.; Alvarez, R.; Schupp, M.; Cristancho, A. G.; Kiser, P. D.; de Lera, A. R.; Lazar, M. A.; Palczewski, K. Stereospecificity of Retinol Saturase: Absolute Configuration, Synthesis, and Biological Evaluation of Dihydroretinoids. J. Am. Chem. Soc., 2008, 130, 1154-1155.
60. Moise, A. R.; Lobo, G. P.; Erokwu, B.; Wilson, D. L.; Peck, D.; Alvarez, S.; Dominguez, M.; Alvarez, R.; Flask, C. A.; de Lera, A. R.; von Lintig, J.; Palczewski, K. Increased adiposity in the retinol saturase-knockout mouse. FASEB J., 2010, 24, 1261-1270.
61. Ruhl, R.; Krzysosiak, A.; Niewiadomska-Cimicka, A.; Rochel, N.; Szeles, L.; Vaz, B.; Wietrzych-Schindler, M.; Alvarez, S.; Szklenar, M.; Nagy, L.; de Lera, A. R.; Krezel, W. 9-cis-13,14-dihydroretinoic acid is an endogenous retinoid acting as RXR ligand in mice. PLoS Genet., 2015, 11, e1005213.
62. Shirley, M. A.; Bennani, Y. L.; Boehm, M. F.; Breau, A. P.; Pathirana, C.; Ulm, E. H. Oxidative and reductive metabolism of 9-cis-retinoic acid in the rat. Identification of 13,14-dihydro-9-cisretinoic acid and its taurine conjugate. Drug Met. Disp., 1996, 24, 293-302.
63. Schmidt, C. K.; Volland, J.; Hamscher, G.; Nau, H. Characterization of a new endogenous vitamin A metabolite. Biochim. Biophys. Acta (BBA) -Mol. Cell Biol. Lip., 2002, 1583, 237-251.
64. Schuchardt, J. P.; Wahlstrom, D.; Ruegg, J.; Giese, N.; Stefan, M.; Hopf, H.; Pongratz, I.; Hakansson, H.; Eichele, G.; Pettersson, K.; Nau, H. The endogenous retinoid metabolite (S)-4-oxo-9-cis-13,14-dihydro-retinoic acid activates retinoic acid receptor signalling both in vitro and in vivo. FEBS J., 2009, 276, 3043-3059.
65. de Urquiza, A. M.; Liu, S.; Sjoberg, M.; Zetterstrom, R. H.; Griffiths, W.; Sjovall, J.; Perlmann, T. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science, 2000, 290, 2140-2144.
66. Goldstein, J. T.; Dobrzyn, A.; Clagett-Dame, M.; Pike, J. W.; DeLuca, H. F. Isolation and characterization of unsaturated fatty acids as natural ligands for the retinoid-X receptor. Arch. Biochem. Biophys., 2003, 420, 185-193.
67. Eager, N. S. C.; Brickell, P. M.; Snell, C.; Wood, J. N. Structural and Functional Evidence for Activation of a Chick Retinoid X Receptor by Eicosanoids. Proc. R. Soc. Lond. Ser. B: Biol. Sci., 1992, 250, 63-69.
68. Kitareewan, S.; Burka, L.; Tomer, B.; Parker, C. E.; Deterding, L. J.; Stevens, R. D.; Forman, B. M.; Mais, D. E.; Heyman, R. A.; McMorris, T.; Weinberger, C. Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol. Cell. Biol., 1996, 7, 1153-1166.
69. LeMotte, P. K.; Keidek, S.; Apfel, C. M. Phytanic acis is a retinoid X receptor ligand. Eur. J. Biochem., 1996, 236, 328-333.
70. Zomer, A. W. M.; van der Burg, B.; Jansen, G. A.; Wanders, R. J. A.; Poll-The, B. T.; van der Saag, P. T. Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor g. J. Lipid Res., 2000, 41, 1801-1807.
71. Harmon, M. A.; Boehm, M. F.; Heyman, R. A.; Mangelsdorf, D. J. Activation of Mammalian Retinoid X Receptors by the Insect Growth Regulator Methoprene. Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 6157-6160.
72. Schoff, P. K.; Ankley, G. T. Effects of methoprene, its metabolites, and breakdown products on retinoid-activated pathways in transfected cell lines. Environ. Toxicol. Chem., 2004, 23, 1305-1310.
73. Kumar, S.; Sandell, L. L.; Trainor, P. A.; Koentgen, F.; Duester, G. Alcohol and aldehyde dehydrogenases: Retinoid metabolic effects in mouse knockout models. Biochim. Biophys. Acta (BBA) -Mol. Cell Biol. Lip., 2012, 1821, 198-205.
74. Ruiz, F. X.; Porte, S.; Pares, X.; Farres, J. Biological role of aldoketo reductases in retinoic acid biosynthesis and signaling. Front. Pharmacol., 2012, 3, 58.
75. Porte, S.; Xavier Ruiz, F.; Gimenez, J.; Molist, I.; Alvarez, S.; Dominguez, M.; Alvarez, R.; de Lera, A. R.; Pares, X.; Farres, J. Aldo-keto reductases in retinoid metabolism: Search for substrate specificity and inhibitor selectivity. Chem. Biol. Interact., 2013, 202, 186-194.
76. Tsujino, T.; Nagata, T.; Katoh, F.; Yamasaki, H. Inhibition of Balb/c 3T3 cell transformation by synthetic acyclic retinoid NIK-333; possible involvement of enhanced gap junctional intercellular communication. Cancer Detect. Prev., 2007, 31, 332-338.
77. Aydemir, G.; Kasiri, Y.; Birta, E.; Beke, G.; Garcia, A. L.; Bartok, E.-M.; Ruhl, R. Lycopene-derived bioactive retinoic acid receptors/ retinoid-X receptors-activating metabolites may be relevant for lycopene's anti-cancer potential. Mol. Nutr. Food Res., 2013, 57, 739-747.
78. Ziouzenkova, O.; Orasanu, G.; Sukhova, G.; Lau, E.; Berger, J. P.; Tang, G.; Krinsky, N. I.; Dolnikowski, G. G.; Plutzky, J. Asymmetric Cleavage of b-Carotene Yields a Transcriptional Repressor of Retinoid X Receptor and Peroxisome Proliferator-Activated Receptor Responses. Mol. Endocrinol., 2007, 21, 77-88.
79. Eroglu, A.; Hruszkewycz, D.; Curley, R. W.; Harrison, E. H. Selected b-apocarotenoids antagonize retinoic acid-induced transactivation of retinoic acid receptors. FASEB J., 2010, 24, 894.
80. Nahoum, V.; Perez, E.; Germain, P.; Rodriguez-Barrios, F.; Manzo, F.; Kammerer, S.; Lemaire, G.; Hirsch, O.; Royer, C. A.; Gronemeyer, H.; de Lera, A. R.; Bourguet, W. Modulators of the structural dynamics of RXR to reveal receptor function. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 17323-17328.
81. Sun, J.; Narayanasamy, S.; Curley, R. W.; Harrison, E. H. b-Apo-13-carotenone Regulates Retinoid X Receptor Transcriptional Activity through Tetramerization of the Receptor. J. Biol. Chem., 2014, 289, 33118-33124.
82. Gampe, R. T.; Montana, V. G.; Lambert, M. H.; Wisely, G. B.; Milburn, M. V.; Xu, H. E. Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. Genes Dev., 2000, 14, 2229-2241.
83. Kotani, H.; Tanabe, H.; Mizukami, H.; Makishima, M.; Inoue, M. Identification of a Naturally Occurring Rexinoid, Honokiol, That Activates the Retinoid X Receptor. J. Nat. Prod., 2010, 73, 1332-1336.
84. Zhang, H.; Xu, X.; Chen, L.; Chen, J.; Hu, L.; Jiang, H.; Shen, X. Molecular Determinants of Magnolol Targeting Both RXRa and PPARg. PLoS One, 2011, 6, e28253.
85. Zhang, H.; Li, L.; Chen, L.; Hu, L.; Jiang, H.; Shen, X. Structure Basis of Bigelovin as a Selective RXR Agonist with a Distinct Binding Mode. J. Mol. Biol., 2011, 407, 13-20.
86. Zhang, H.; Zhou, R.; Li, L.; Chen, J.; Chen, L.; Li, C.; Ding, H.; Yu, L.; Hu, L.; Jiang, H.; Shen, X. Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor. J. Biol. Chem., 2011, 286, 1868-1875.
87. Wang, G.-H.; Jiang, F.-Q.; Duan, Y.-H.; Zeng, Z.-P.; Chen, F.; Dai, Y.; Chen, J.-B.; Liu, J.-X.; Liu, J.; Zhou, H.; Chen, H.-F.; Zeng, J.-Z.; Su, Y.; Yao, X.-S.; Zhang, X.-K. Targeting Truncated Retinoid X Receptor-a by CF31 Induces TNF-a-Dependent Apoptosis. Cancer Res., 2013, 73, 307-318.
88. Klaholz, B. P.; Renaud, J.-P.; Mitschler, A.; Zusi, C.; Chambon, P.; Gronemeyer, H.; Moras, D. Conformational adaptation of agonists to the human nuclear receptor RARg. Nat. Struct. Biol., 1998, 5, 199-202.
89. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe Jr., R. T.; McKee, D. D.; Moore, J. T.; M., W. T. Structural determinants of ligand binding selectivity between the peroxisome proliferator activated receptors. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 13919-13924.
90. Loeliger, P.; Bollag, W.; Mayer, H. Arotinoids: a new class of highly active retinoids. Eur. J. Med. Chem., 1980, 15, 9-15.
91. Alvarez, S.; Pazos-Randulfe, Y.; Khanwalkar, H.; Germain, P.; Alvarez, R.; Gronemeyer, H.; de Lera, A. R. New retinoid chemotypes: 9-cis-retinoic acid analogs with hydrophobic rings derived from terpenes as selective RAR agonists. Bioorg. Med. Chem., 2008, 16, 9719-9728.
92. Okitsu, T.; Sato, K.; Iwatsuka, K.; Sawada, N.; Nakagawa, K.; Okano, T.; Yamada, S.; Kakuta, H.; Wada, A. Replacement of the hydrophobic part of 9-cis-retinoic acid with cyclic terpenoid moiety results in RXR-selective agonistic activity. Bioorg. Med. Chem., 2011, 19, 2939-2949.
93. Alvarez, R.; Vega, M. J.; Kammerer, S.; Rossin, A.; Germain, P.; Gronemeyer, H.; de Lera, A. R. 9-cis-retinoic Acid Analogues With Bulky Hydrophobic Rings: New RXR-Selective Agonists. Bioorg. Med. Chem. Lett., 2004, 12, 6117-6122.
94. Zhang, L.; Nadzan, A. M.; Heyman, R. A.; Love, D. L.; Mais, D. E.; Croston, G.; Lamph, W. W.; Boehm, M. F. Discovery of Novel Retinoic Acid Receptor Agonists Having Potent Antiproliferative Activity in Cervical Cancer Cells. J. Med. Chem., 1996, 39, 2659-2663.
95. Bennani, J. L.; Marron, K. S.; Mais, D. E.; Flatten, K.; Nadzan, A. M.; Boehm, M. F. Synthesis and Characterization of a Highly Potent and Selective Isotopically Labeled Retinoic Acid Receptor Ligand, ALRT1550. J. Org. Chem., 1998, 63, 543-550.
96. Dominguez, B.; Vega, M. J.; Sussman, F.; de Lera, A. R. Synthesis and Characterization of a New RXR Agonist Based on the 6-tert-Butyl-1,1-dimethylindanyl Structure. Bioorg. Med. Chem. Lett., 2002, 12, 2607-2609.
97. Michellys, P. Y.; Ardecky, R. A.; Chen, J.-H.; Crombie, D. L.; Etgen, G. J.; Faul, M. M.; Faulkner, A. L.; Grese, T. A.; Heyman, R. A.; Karanewsky, D. S.; Klausing, K.; Leibowitz, M. D.; Liu, S.; Mais, D. A.; Mapes, C. M.; Marchske, K. B.; Reifel-Miller, A.; Ojilvie, K. M.; Rungta, D.; Thompson, A. W.; Tyhonas, J. S.; Boehm, M. F. Novel (2E,4E,6Z)-7-(2-Alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic Acid Retinoid X Receptor Modulators Are Active in Models of Type 2 Diabetes. J. Med. Chem., 2003, 46, 2683-2696.
98. Haffner, C. D.; Lenhard, J. M.; Miller, A. B.; McDougald, D. L.; Dwornik, K.; Ittoop, O. R.; Gampe, R. T.; Xu, H. E.; Blanchard, S.; Montana, V. G.; Consler, T. G.; Bledsoe, R. K.; Ayscue, A.; Croom, D. Structure-based Design of Potent Retinoid X Receptor a Agonists. J. Med. Chem., 2004, 47, 2010-2029.
99. Michellys, P. Y.; Ardecky, R. A.; Chen, J.-H.; D’Arrigo, J.; Grese, T. A.; Karanewsky, D. S.; Leibowitz, M. D.; Liu, S.; Mais, D. A.; Mapes, C. M.; Montrose-Rafizadeh, C.; Ojilvie, K. M.; Reifel-Miller, A.; Rungta, D.; Thompson, A. W.; Tyhonas, J. S.; Boehm, M. F. Design, Synthesis and Structure-Activity Relationship Studies of Novel 6,7-Locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic Acids. J. Med. Chem., 2003, 46, 4087-4103.
100. Leibowitz, M. D.; Ardecky, R. J.; Boehm, M. F.; Broderick, C. L.; Carfagna, M. A.; Crombie, D. L.; D'Arrigo, J.; Etgen, G. J.; Faul, M. M.; Grese, T. A.; Havel, H.; Hein, N. I.; Heyman, R. A.; Jolley, D.; Klausing, K.; Liu, S.; Mais, D. E.; Mapes, C. M.; Marschke, K. B.; Michellys, P.-Y.; Montrose-Rafizadeh, C.; Ogilvie, K. M.; Pascual, B.; Rungta, D.; Tyhonas, J. S.; Urcan, M. S.; Wardlow, M.; Yumibe, N.; Reifel-Miller, A. Biological Characterization of a Heterodimer-Selective Retinoid X Receptor Modulator: Potential Benefits for the Treatment of Type 2 Diabetes. Endocrinol., 2006, 147, 1044-1053.
101. Gernert, D. L.; Ajamie, R.; Ardecky, R. A.; Bell, M. G.; Leibowitz, M. D.; Mais, D. A.; Mapes, C. M.; Michellys, P. Y.; Rungta, D.; Reifel-Miller, A.; Tyhonas, J. S.; Yumibe, N.; Grese, T. A. Design and Synthesis of Fluorinated RXR Modulators. Bioorg. Med. Chem. Lett., 2003, 13, 3191-3195.
102. Canan-Koch, S. S.; Dardashti, L. J.; Cesario, R. M.; Croston, G. E.; Boehm, M. F.; Heyman, R. A.; Nadzan, A. M. Synthesis of Retinoid X Receptor-Specific Ligands That Are Potent Inducers of Adipogenesis in 3T3-L1 Cells. J. Med. Chem., 1999, 42, 742-750.
103. Canan Koch, S. S.; Dardashti, L. J.; Hebert, J. J.; White, S. K.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Identification of the First Retinoid X Receptor Homodimer Antagonist. J. Med. Chem., 1996, 39, 3229-3234.
104. Schulman, I. G.; Li, C.; Schwabe, J. W.; Evans, R. M. The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. Genes Dev., 1997, 11, 299-308.
105. Deng, T.; Shan, S.; Li, Z.-B.; Wu, Z.-W.; Liao, C.-Z.; Ko, B.; Lu, X.-P.; Cheng, J.; Ning, Z.-Q. A New Retinoid-Like Compound That Activates Peroxisome Proliferator-Activated Receptors and Lowers Blood Glucose in Diabetic Mice. Biol. Pharm. Bull., 2005, 28, 1192-1196.
106. Hibi, S.; Kikuchi, K.; Yoshimura, H.; Nagai, M.; Tai, K.; Hida, T. Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor Agonists. J. Med. Chem., 1998, 41, 3245-3252.
107. Muccio, D. D.; Brouillette, W. J.; Breitman, T. R.; Taimi, M.; Emanuel, P. D.; Zhang, X.-k.; Chen, G.-q.; Sani, B. P.; Venepally, P.; Reddy, L.; Alam, M.; Simpson-Herren, L.; Hill, D. L. Conformationally Defined Retinoid Acid Analogues. 4. Potential New Agents for Acute Promielocytic and Juvenile Myelomonocytic Leukemias. J. Med. Chem., 1998, 41, 1679-1687.
108. Atigadda, V. R.; Vines, K. K.; Grubbs, C. J.; Hill, D. L.; Beenken, S. L.; Bland, K. I.; Brouillette, W. J.; Muccio, D. D. Conformationally Defined Retinoic Acid Analogues. 5. Large-Scale Synthesis and Mammary Cancer Chemopreventive Activity for (2E,4E,6Z,8E)-8-(3',4'-Dihydro-1'(2'H)-naphathalen-1'ylidene)-3,7-dimethyl-2,4,6-octatienoic Acid. J. Med. Chem., 2003, 46, 3766-3769.
109. Grubbs, C. J.; Lubet, R. A.; Atigadda, V. R.; Christov, K.; Deshpande, A. M.; Tirmal, V.; Xia, G.; Bland, K. I.; Eto, I.; Brouillette, W. J.; Muccio, D. D. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis, 2006, 27, 1232-1239.
110. Kolesar, J. M.; Hoel, R.; Pomplun, M.; Havighurst, T.; Stublaski, J.; Wollmer, B.; Krontiras, H.; Brouillette, W.; Muccio, D.; Kim, K.; Grubbs, C. J.; Bailey, H. E. A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. Cancer Prev. Res., 2010, 3, 1565-1570.
111. Kapetanovic, I. M.; Horn, T. L.; Johnson, W. D.; Cwik, M. J.; Detrisac, C. J.; McCormick, D. L. Murine Oncogenicity and Pharmacokinetics Studies of 9-cis-UAB30, an RXR Agonist, for Breast Cancer Chemoprevention. Int. J. Toxicol., 2010, 29, 157-164.
112. Desphande, A.; Xia, G.; Boerma, L. J.; Vines, K. K.; Atigadda, V. R.; Lobo-Ruppert, S.; Grubbs, C. J.; Moeinpour, F. L.; Smith, C. D.; Christov, K.; Brouillette, W. J.; Muccio, D. D. Methylsubstituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention. Bioorg. Med. Chem., 2014, 22, 178-185.
113. Atigadda, V. R.; Xia, G.; Desphande, A.; Boerma, L. J.; Lobo-Ruppert, S.; Grubbs, C. J.; Smith, C. D.; Brouillette, W. J.; Muccio, D. D. Methyl Substitution of a Rexinoid Agonist Improves Potency and Reveals Site of Lipid Toxicity. J. Med. Chem., 2014, 57, 5370-5380.
114. Farmer, L. J.; Zhi, L.; Jeong, S.; Kallel, E. A.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Synthesis and structureactivity relationships of potent conformationally restricted retinoid X receptor ligands. Bioorg. Med. Chem. Lett., 1997, 7, 2747-2752.
115. Dawson, M. I.; Jong, L.; Hobbs, P. D.; Cameron, J. F.; Chao, W.-r.; Pfahl, M.; Lee, M.-O.; Shroot, B.; Pfahl, M. Conformational Effects on Retinoid Receptor Selectivity. 2. Effects of Retinoid Bridging Group on Retinoid X Receptor Activity and Selectivity. J. Med. Chem., 1995, 38, 3368-3383.
116. Farmer, L. J.; Zhi, L.; Jeong, S.; Lamph, W. W.; Osburn, D. L.; Croston, G.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Retinoic Acid Receptor Ligands Based on the 6-Cyclopropyl-2,4-hexadienoic Acid. Bioorg. Med. Chem. Lett., 2003, 13, 261-264.
117. Farmer, L. J.; Marron, K. S.; Canan Koch, S. S.; Hwang, C. K.; Kallel, E. A.; Zhi, L.; Nadzan, A. M.; Robertson, D. W.; Bennani, Y. L. Aza-retinoids as novel retinoid X receptor-specific agonists. Bioorg. Med. Chem. Lett., 2006, 16, 2352-2356.
118. Apfel, C. M.; Kamber, M.; Klaus, M.; Mohr, P.; Keidel, S.; LeMotte, P. K. Enhancement of HL-60 Differentiation by a New Class of Retinoids with Selective Activity on Retinoid X Receptor. J. Biol. Chem., 1995, 270, 30765-30772.
119. Vuligonda, V.; Lin, Y.; Chandraratna, R. A. S. Synthesis of highly potent RXR-specific retinoids: The use of a cyclopropyl group as a double bond isostere. Bioorg. Med. Chem. Lett., 1996, 6, 213-218.
120. Farmer, L. J.; Jeong, S.; Kallel, E. A.; Canan Koch, S. S.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Synthesis and structure-activity relationships of potent retinoid X receptor ligands. Bioorg. Med. Chem. Lett., 1997, 7, 2393-2398.
121. Michellys, P. Y.; D’Arrigo, J.; Grese, T. A.; Karanewsky, D. S.; Leibowitz, M. D.; Mais, D. A.; Mapes, C. M.; Reifel-Miller, A.; Rungta, D.; Boehm, M. F. Design, synthesis and structure-activity relationship of novel RXR-selective modulators. Bioorg. Med. Chem. Lett., 2004, 14, 1593-1598.
122. Gernert, D. L.; Neel, D. A.; Boehm, M. F.; Leibowitz, M. D.; Mais, D. E.; Michellys, P. Y.; Rungta, D.; Reifer-Miller, A.; Grese, T. A. Design and synthesis of benzofused heterocyclic RXR modulators. Bioorg. Med. Chem. Lett., 2004, 14, 2759-2763.
123. Beard, R. L.; Gil, D. W.; Marler, D. K.; Henry, E.; Colon, D. F.; Gillett, S. J.; Arefieg, T.; Breen, T. S.; Krauss, H.; Davies, P. J. A.; Chandraratna, R. A. S. Structural Basis for the Differential RXR & RAR Activity of Stilbene Retinoid Analogs. Bioorg. Med. Chem. Lett., 1994, 4, 1447-1452.
124. Beard, R. L.; Chandraratna, R. A. S.; Colon, D. F.; Gillett, S. J.; Henry, E.; Marler, D. K.; Song, T.; Denys, L.; Garst, M. E.; Arefieg, T.; Klien, E.; Gil, D. W.; Wheeler, D. M.; Kochhar, D. M.; Davies, P. J. A. Synthesis and Structure-Activity Relationships of Stilbene Retinoid Analogs Substituted with Heteroaromatic Carboxylic Acids. J. Med. Chem., 1995, 38, 2820-2829.
125. Boehm, M. F.; Zhang, L.; Badea, B. A.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; Goldman, M. E.; Heyman, R. A. Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids. J. Med. Chem., 1994, 37, 2930-2941.
126. Lehmann, J.; Jong, L.; Fanjul, A.; Cameron, J.; Lu, X.; Haefner, P.; Dawson, M.; Pfahl, M. Retinoids selective for retinoid X receptor response pathways. Science, 1992, 258, 1944-1946.
127. Boehm, M. F.; Zhang, L.; Zhi, L.; McClurg, M. R.; Berger, E.; Wagoner, M.; Mais, D. E.; Suto, C. M.; Davies, P. J. A.; Heyman, R. A.; Nadzan, A. M. Design and Synthesis of Potent Retinoid X Receptor Selective Ligands That Induce Apoptosis in Leukemia Cells. J. Med. Chem., 1995, 38, 3146-3155.
128. Tanaka, T.; De Luca, L. M. Therapeutic Potential of "Rexinoids" in Cancer Prrevention and Treatment. Cancer Res., 2009, 69, 4945-4947.
129. Sherman, S. I.; Gopal, J.; Haugen, B. R.; Chiu, A. C.; Whaley, K.; Nowlakha, P.; Duvic, M. Central Hypothyroidism Associated with Retinoid X Receptor-Selective Ligands. New Engl. J. Med., 1999, 340, 1075-1079.
130. Cavasotto, C. N.; Liu, G.; James, S. Y.; Hobbs, P. D.; Peterson, V. J.; Bhattacharya, A. A.; Kolluri, S. K.; Zhang, X.-k.; Leid, M.; Abagyan, R.; Liddington, R. C.; Dawson, M. I. Determinants of Retinoid X Receptor Transcriptional Antagonism. J. Med. Chem., 2004, 47, 4360-4372.
131. Faul, M. M.; Ratz, A. M.; Sullivan, K. A.; Trankle, W. G.; Winneroski, L. L. Synthesis of Novel Retinoid X Receptor-Selective Retinoids. J. Org. Chem., 2001, 66, 5772-5782.
132. Daiss, J. O.; Burschka, C.; Mills, J. S.; Montana, J. G.; Showell, G. A.; Fleming, I.; Gaudon, C.; Ivanova, D.; Gronemeyer, H.; Tacke, R. Synthesis, Crystal Structure Analysis, and Pharmacological Characterization of Disila-bexarotene, a Disila-Analogue of the RXR-Selective Retinoid Agonist Bexarotene. Organometallics, 2005, 24, 3192-3199.
133. Lippert, W. P.; Christian, B.; Kathrin, G.; Martin, K.; Diana, I.; Claudine, G.; Yoshiteru, S.; Pierre, A.; Natacha, R.; Dino, M.; Hinrich, G.; Reinhold, T. Silicon Analogues of the RXR-Selective Ret inoid Agonist SR11237 (BMS649): Chemistry and Biology. ChemMedChem., 2009, 4, 1143-1152.
134. Furmick, J. K.; Kaneko, I.; Walsh, A. N.; Yang, J.; Bhogal, J. S.; Gray, G. M.; Baso, J. C.; Browder, D. O.; Prentice, J. L. S.; Montano, L. A.; Huynh, C. C.; Marcus, L. M.; Tsosie, D. G.; Kwon, J. S.; Quezada, A.; Reyes, N. M.; Lemming, B.; Saini, P.; van der Vaart, A.; Groy, T. L.; Marshall, P. A.; Jurutka, P. W.; Wagner, C. E. Modeling, Synthesis and Biological Evaluation of Potential Retinoid X Receptor-Selective Agonists: Novel Halogenated Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl] benzoic Acid (Bexarotene). Chem Med Chem., 2012, 7, 1551-1566.
135. Wagner, C. E.; Jurutka, P. W.; Marshall, P. A.; Groy, T. L.; van der Vaart, A.; Ziller, J. W.; Furmick, J. K.; Graeber, M. E.; Matro, E.; Miguel, B. V.; Tran, I. T.; Kwon, J.; Tedeschi, J. N.; Moosavi, S.; Danishyar, A.; Philp, J. S.; Khamees, R. O.; Jackson, J. N.; Grupe, D. K.; Badshah, S. L.; Hart, J. W. Modeling, Synthesis and Biological Evaluation of Potential Retinoid X Receptor (RXR) Selective Agonists: Novel Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene). J. Med. Chem., 2009, 52, 5950-5966.
136. Chen, G.-L.; Wang, L.-H.; Wang, J.; Chen, K.; Zhao, M.; Sun, Z.-Z.; Wang, S.; Zheng, H.-L.; Yang, J.-Y.; Wu, C.-F. Discovery of a small molecular compound simultaneously targeting RXR and HADC: Design, synthesis, molecular docking and bioassay. Bioorg. Med. Chem. Lett., 2013, 23, 3891-3895.
137. Winum, J.-Y.; Baghdiguian, S.; Commes, T.; Leydet, A.; Montero, J.-L. Synthesis of New TargretinR Analogues that Induce Apoptosis in Leukemia HL-60 Cells. Bioorg. Med. Chem. Lett., 2002, 12, 3529-3532.
138. Bauer, J. B.; Lippert, W. P.; Dorrich, S.; Tebbe, D.; Burschka, C.; Christie, V. B.; Tams, D. M.; Henderson, A. P.; Murray, B. A.; Marder, T. B.; Przyborski, S. A.; Tacke, R. Novel Silicon-Containing Analogues of the Retinoid Agonist Bexarotene: Syntheses and Biological Effects on Human Pluripotent Stem Cells. ChemMedChem., 2011, 6, 1509-1517.
139. Shankaranarayanan, P.; Rossin, A.; Khanwalkar, H.; Alvarez, S.; Alvarez, R.; Jacobson, A.; Nebbioso, A.; de Lera, A. R.; Altucci, L.; Gronemeyer, H. Growth Factor-Antagonized Rexinoid Apoptosis Involves Permissive PPARg/RXR Heterodimers to Activate the Intrinsic Death Pathway by NO. Cancer Cell, 2009, 16, 220-231.
140. Fanjul, A.; Dawson, N. I.; Hobbs, P. D.; Jong, L.; Cameron, J. F.; Harlev, E.; Graupner, G.; Lu, X.-P.; Pfahl, M. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature, 1994, 372, 107-111.
141. Diaz, P.; Gendre, F.; Stella, L.; Charpentier, B. New Synthetic Retinoids Obtained by Palladium-Catalyzed Tandem Cyclisation-Hydride Capture Process. Tetrahedron, 1998, 54, 4579-4590.
142. Perez-Santin, E.; Germain, P.; Quillard, F.; Khanwalkar, H.; Rodriguez-Barrios, F.; Gronemeyer, H.; de Lera, A. R.; Bourguet, W. Modulating Retinoid X Receptor with a Series of (E)-3-[4-Hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic Acids and Their 4-Alkoxy Isomers. J. Med. Chem., 2009, 52, 3150-3158.
143. Pfahl, M.; Tachdjian, C.; Al-Shamma, H.; Giachino, A. F.; Jakubowicz-Jaillardon, K.; Guo, J. P.; Boudjelal, M.; Zapf, J. W. WO 2003075924 A1.
144. Lagu, B.; Pio, B.; Lebedev, R.; Yang, M.; Pelton, P. D. RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia. Bioorg. Med. Chem. Lett., 2007, 17, 3497-3503.
145. Lagu, B.; Lebedev, R.; Pio, B.; Yang, M.; Pelton, P. D. Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia. Bioorg. Med. Chem. Lett., 2007, 17, 3491-3496.
146. Perez-Rodriguez, S.; Ortiz, M. A.; Pereira, R.; Rodriguez-Barrios, F.; de Lera, A. R.; Piedrafita, F. J. Highly twisted adamantyl arotinoids: Synthesis, antiproliferative effects and RXR transactivation profiles. Eur. J. Med. Chem., 2009, 44, 2434-2446.
147. Garcia, J.; Khanwalkar, H.; Pereira, R.; Erb, C.; Voegel, J. J.; Collette, P.; Mauvais, P.; Bourguet, W.; Gronemeyer, H.; de Lera, A. R. Pyrazine Arotinoids with Inverse Agonist Activities on the Retinoid and Rexinoid Receptors. ChemBioChem., 2009, 10, 1252-1259.
148. Dawson, M. I.; Jong, L.; Hobbs, P. D.; Xiao, D.; Feng, K.-C.; Chao, W.-r.; Pan, C.; Fontana, J. A.; Zhang, X.-k. 4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)phenyl]benzoic Acid and Heterocyclic-Bridged Analogues Are Novel Retinoic Acid Receptor Subtype and Retinoid X Receptor a Agonists. Bioorg. Med. Chem. Lett., 2000, 10, 1311-1313.
149. Ohta, K.; Kawachi, E.; Fukasawa, H.; Shudo, K.; Kagechika, H. Diphenylamine-based retinoid antagonists: Regulation of RAR and RXR function depending on the N-substituent. Bioorg. Med. Chem., 2011, 19, 2501-2507.
150. Ohta, K.; Tsuji, M.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Shudo, K.; Kagechika, H. Potent Retinoid Synergists with a Diphenylamine Skeleton. Biol. Pharm. Bull., 1998, 21, 544-546.
151. Ohta, K.; Iijima, T.; Kawachi, E.; Kagechika, H.; Endo, Y. Novel retinoid X receptor (RXR) antagonists having a dicarba-closododecaborane as a hydrophobic moiety. Bioorg. Med. Chem. Lett., 2004, 14, 5913-5918.
152. Takahashi, B.; Ohta, K.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Kagechika, H. Novel Retinoid X Receptor Antagonists: Specific Inhibition of Retinoid Synergism in RXR-RAR Heterodimers. J. Med. Chem., 2002, 45, 3327-3329.
153. Morishita, K.; Yakushiji, N.; Ohsawa, F.; Takamatsu, K.; Matsuura, N.; Makishima, M.; Kawahata, M.; Yamaguchi, K.; Tai, A.; Sasaki, K.; Kakuta, H. Replacing alkyl sulfonamide with aromatic sulfonamide in sulfonamide-type RXR agonists favors switch towards antagonist activity. Bioorg. Med. Chem. Lett., 2009, 19, 1001-1003.
154. Ohta, K.; Kawachi, E.; Shudo, K.; Kagechika, H. Structure-activity relationship study on benzoic acid part of diphenylamine-based retinoids. Bioorg. Med. Chem. Lett., 2013, 23, 81-84.
155. Fujii, S.; Ohsawa, F.; Yamada, S.; Shinozaki, R.; Fukai, R.; Makishima, M.; Enomoto, S.; Tai, A.; Kakuta, H. Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation. Bioorg. Med. Chem., 2010, 20, 5139-5142.
156. Ebisawa, M.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Itai, A.; Shudo, K.; Kagechika, H. Novel Thiazolidinedione Derivatives with Retinoid Synergistic Activity. Biol. Pharm. Bull., 1998, 21, 547-549.
157. Beard, R. L.; Colon, D. F.; Song, T. K.; Daies, P. J. A.; Kochlar, D. M.; Chandraratna, R. A. S. Synthesis and Structure-Activity Relationships of Retinoid X Receptor-Selective Diaryl Sulfide Analogs of Retinoic Acid. J. Med. Chem., 1996, 39, 3556-3563.
158. Millois, C.; Diaz, P. Solution-Phase Synthesis of Diaryl Selenides Using Polymer-Supported Borohydride. Org. Lett., 2000, 2, 1705-1708.
159. Kakuta, H.; Yakushiji, N.; Shinozaki, R.; Ohsawa, F.; Yamada, S.; Ohta, Y.; Kawata, K.; Nakayama, M.; Hagaya, M.; Fujiwara, C.; Makishima, M.; Uno, S.; Tai, A.; Maehara, A.; Nakayama, M.; Oohashi, T.; Yasui, H.; Yoshikawa, Y. RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists. ACS Med. Chem. Lett., 2012, 3, 427-432.
160. Ohsawa, F.; Yamada, S.; Yakushiji, N.; Shinozaki, R.; Nakayama, M.; Kawata, K.; Hagaya, M.; Kobayashi, T.; Kohara, K.; Furusawa, Y.; Fujiwara, C.; Ohta, Y.; Makishima, M.; Naitou, H.; Tai, A.; Yoshikawa, Y.; Yasui, H.; Kakuta, H. Mechanism of Retinoid X Receptor Partial Agonistic Action of 1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic Acid and Structural Development To Increase Potency. J. Med. Chem., 2013, 56, 1865-1877.
161. Takamatsu, K.; Takano, A.; Yakushiji, N.; Morohashi, K.; Morishita, K.; Matsuura, N.; Makishima, M.; Tai, A.; Sasaki, K.; Kakuta, H. The First Potent Subtype-Selective Retinoid X Receptor (RXR) Agonist Possessing a 3-Isopropoxy-4-isopropylphenylamino Moiety, NEt-3IP (RXRa/b-dual agonist). ChemMedChem., 2008, 3, 780-787.
162. Ohsawa, F.; Morishita, K.-i.; Yamada, S.; Makishima, M.; Kakuta, H. Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers. ACS Med. Chem. Lett., 2010, 1, 521-525.
163. Nakayama, M.; Yamada, S.; Ohsawa, F.; Ohta, Y.; Kawata, K.; Makishima, M.; Kakuta, H. Discovery of a Potent Retinoid X Re ceptor Antagonist Structurally Closely Related to RXR Agonist NEt-3IB. ACS Med. Chem. Lett., 2011, 2, 896-900.
164. Takamatsu, K.; Takano, A.; Yakushiji, N.; Morishita, K.; Matsuura, N.; Makishima, M.; Ali, H. I.; Akaho, E.; Tai, A.; Sasaki, K.; Kakuta, H. Reduction of Lipophilicity at the Lipophilic Domain of RXR Agonists Enables Production of Subtype Preference: RXRa-Preferential Agonist Possessing a Sulfonamide Moiety. ChemMedChem., 2008, 3, 454-460.
165. Kawata, K.; Morishita, K.-i.; Nakayama, M.; Yamada, S.; Kobayashi, T.; Furusawa, Y.; Arimoto-Kobayashi, S.; Oohashi, T.; Makishima, M.; Naitou, H.; Ishitsubo, E.; Tokiwa, H.; Tai, A.; Kakuta, H. RXR Partial Agonist Produced by Side Chain Repositioning of Alkoxy RXR Full Agonist Retains Antitype 2 Diabetes Activity without the Adverse Effects. J. Med. Chem., 2015, 58, 912-926.
166. Yamada, S.; Ohsawa, F.; Fujii, S.; Shinozaki, R.; Makishima, M.; Naitou, H.; Enomoto, S.; Tai, A.; Kakuta, H. Fluorescent retinoid X receptor ligands for fluorescence polarization assay. Bioorg. Med. Chem. Lett., 2010, 20, 5143-5146.
167. Wallen-Mackenzie, O.; Mata de Urquiza, A.; Petersson, S.; Rodriguez, F. J.; Friling, S.; Wagner, J.; Ordentlich, P.; Lengqvist, J.; Heyman, R. A.; Arenas, E.; Perlmann, T. Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells. Genes Dev., 2003, 17, 3036-3047.
168. Umemiya, H.; Fukasawa, H.; Ebisawa, M.; Eyrolles, L.; Kawachi, E.; Eisenmann, G.; Gronemeyer, H.; Hashimoto, Y.; Shudo, K.; Kagechika, H. Regulation of Retinoidal Actions by Diazepinylbenzoic Acids. Retinoid Synergists Activate the RXR-RAR Heterodimers. J. Med. Chem., 1997, 40, 4222-4234.
169. Morita, K.; Kawana, K.; Sodeyama, M.; Shimomura, I.; Kagechika, H.; Makishima, M. Selective allosteric ligand activation of the retinoid X receptor heterodimers of NGFI-B and Nurr1. Biochem. Pharmacol., 2005, 71, 98-107.
170. Ebisawa, M.; Umemiya, H.; Ohta, K.; Fukasawa, H.; Kawachi, E.; Christoffel, G.; Gronemeyer, H.; Tsuji, M.; Hashimoto, Y.; Shudo, K.; Kagechika, H. Retinoid X Receptor-Antagonistic Diazepinylbenzoic Acids. Chem. Pharm. Bull., 1999, 47, 1778-1786.
171. Shulman, A. I.; Larson, C.; Mangelsdorf, D. J.; Ranganathan, R. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell, 2004, 116, 417-429.
172. Sakaki, J.; Kishida, M.; Konishi, K.; Gunji, H.; Toyao, A.; Matsumoto, Y.; Kanazawa, T.; Uchiyama, H.; Fukaya, H.; Mitani, H.; Arai, Y.; Kimura, M. Synthesis and structure-activity relationship of novel RXR antagonists: Orally active anti-diabetic and antiobesity agents. Bioorg. Med. Chem. Lett., 2007, 17, 4804-4807.
173. Sakaki, J.; Konishi, K.; Kishida, M.; Gunji, H.; Kanazawa, T.; Uchiyama, H.; Fukaya, H.; Mitani, H.; Kimura, M. Synthesis and structure-activity relationship of RXR antagonists based on the diazepinylbenzoic acid structure. Bioorg. Med. Chem. Lett., 2007, 17, 4808-4811.
174. Dawson, M. I.; Ye, M.; Cao, X.; Farhana, L.; Hu, Q.-Y.; Zhao, Y.; Xu, L. P.; Kiselyuk, A.; Correa, R. G.; Yang, L.; Hou, T.; Reed, J. C.; Itkin-Ansari, P.; Levine, F.; Sanner, M. F.; Fontana, J. A.; Zhang, X.-K. Derivation of a Retinoid X Receptor Scaffold from Peroxisome Proliferator-Activated Receptor γ Ligand 1-Di (1H-indol-3-yl)methyl-4-trifluoromethylbenzene. ChemMedChem., 2009, 4, 1106-1119.
175. Orlandi, M.; Mantovani, B.; Ammar, K.; Avitabile, E.; Dal Monte, P.; Bartolini, G. Retinoids and Cancer: Antitumoral Effects of ATRA, 9-cis-RA and the New Retinoid IIF on the HL-60 Leukemic Cell Line. Med. Princ. Pract., 2003, 12, 164-169.
176. Papi, A.; Rocchi, P.; Ferreri, A. M.; Guerra, F.; Orlandi, M. Enhanced effects of PPARγ ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. Oncol. Rep., 2009, 21, 1083-1089.
177. Park, E.-J.; Kondratyuk, T. P.; Morrell, A.; Kiselev, E.; Conda-Sheridan, M.; Cushman, M.; Ahn, S.; Choi, Y.; White, J. J.; van Breemen, R. B.; Pezzuto, J. M. Induction of Retinoid X Receptor Activity and Consequent Upregulation of p21WAF1/CIP1 by Indenoisoquinolines in MCF7 Cells. Cancer Prev. Res., 2011, 4, 592-607.
178. Conda-Sheridan, M.; Park, E.-J.; Beck, D. E.; Reddy, P. V. N.; Nguyen, T. X.; Hu, B.; Chen, L.; White, J. J.; van Breemen, R. B.; Pezzuto, J. M.; Cushman, M. Design, Synthesis, and Biological Evaluation of Indenoisoquinoline Rexinoids with Chemopreventive Potential. J. Med. Chem., 2013, 56, 2581-2605.
179. Nguyen, T. X.; Abdelmalak, M.; Marchand, C.; Agama, K.; Pommier, Y.; Cushman, M. Synthesis and Biological Evaluation of Nitrated 7-, 8-, 9-, and 10-Hydroxyindenoisoquinolines as Potential Dual Topoisomerase I (Top1)-Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors. J. Med. Chem., 2015, 58, 3188-3208.
180. Kolluri, S. K.; Corr, M.; James, S. Y.; Bernasconi, M.; Lu, D.; Liu, W.; Cottam, H. B.; Leoni, L. M.; Carson, D. A.; Zhang, X.-k. The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 2525-2530.
181. Zhou, H.; Liu, W.; Su, Y.; Wei, Z.; Liu, J.; Kolluri, S. K.; Wu, H.; Cao, Y.; Chen, J.; Wu, Y.; Yan, T.; Cao, X.; Gao, W.; Molotkov, A.; Jiang, F.; Li, W.-G.; Lin, B.; Zhang, H.-P.; Yu, J.; Luo, S.-P.; Zeng, J.-Z.; Duester, G.; Huang, P.-Q.; Zhang, X.-K. NSAID Sulindac and Its Analog Bind RXRa and Inhibit RXRa-Dependent AKT Signaling. Cancer Cell, 2010, 17, 560-573.
182. Wang, Z.-G.; Chen, L.; Chen, J.; Zheng, J.-F.; Gao, W.; Zeng, Z.; Zhou, H.; Zhang, X.-k.; Huang, P.-Q.; Su, Y. Synthesis and SAR study of modulators inhibiting tRXRa-dependent AKT activation. Eur. J. Med. Chem., 2013, 62, 632-648.
183. Chen, L.; Wang, Z.-G.; Aleshin, A. E.; Chen, F.; Chen, J.; Jiang, F.; Alitongbieke, G.; Zeng, Z.; Ma, Y.; Huang, M.; Zhou, H.; Cadwell, G.; Zheng, J.-F.; Huang, P.-Q.; Liddington, R. C.; Zhang, X.-k.; Su, Y. Sulindac-Derived RXRa Modulators Inhibit Cancer Cell Growth by Binding to a Novel Site. Chem. Biol., 2014, 21, 596-607.
184. Chen, F.; Liu, J.; Huang, M.; Hu, M.; Su, Y.; Zhang, X.-k. Identification of a New RXRa Antagonist Targeting the Coregulator-Binding Site. ACS Med. Chem. Lett., 2014, 5, 736-741.
185. Dawson, M. I.; Fontana, J. A. The Peptidomimetic, 1-Adamantyl-Substituted, and Flex-Het Classes of Retinoid-Derived Molecules: Their Structure-Activity Relationships and Retinoid Receptor-Independent Anticancer Activities. Mini Rev. Med. Chem., 2010, 10, 455-491.
186. Zacheis, D.; Dhar, A.; Lu, S.; Madler, M. M.; Klucik, J.; Brown, C. W.; Liu, S.; Clement, F.; Subramanian, S.; Weerasekare, G. M.; Berlin, K. D.; Gold, M. A.; Houck, J. R.; Fountain, K. R.; Benbrook, D. M. Heteroarotinoids Inhibit Head and Neck Cancer Cell Lines in Vitro and in Vivo Through Both RAR and RXR Retinoic Acid Receptors. J. Med. Chem., 1999, 42, 4434-4445.
187. Benbrook, D.; Kamelle, S.; Guruswamy, S.; Lightfoot, S.; Rutledge, T.; Gould, N.; Hannafon, B.; Dunn, S. T.; Berlin, K. D. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Inv. New Drugs, 2005, 23, 417-428.
188. Zeng, Z.; Sun, Z.; Huang, M.; Zhang, W.; Liu, J.; Chen, L.; Chen, F.; Zhou, Y.; Lin, J.; Huang, F.; Xu, L.; Zhuang, Z.; Guo, S.; Alitongbieke, G.; Xie, G.; Xu, Y.; Lin, B.; Cao, X.; Su, Y.; Zhang, X.-k.; Zhou, H. Nitrostyrene Derivatives Act as RXRa Ligands to Inhibit TNFa Activation of NF-kB. Cancer Res., 2015, 75, 2049-2060.
189. Ebisawa, M.; Ohta, K.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Kagechika, H. Novel Retinoidal Tropolone Derivatives. Bioisosteric Relationship of Tropolone Ring with Benzoic Acid Moiety in Retinoid Structure. Chem. Pharm. Bull., 2001, 49, 501-503.
190. Martinez, C.; Lieb, M.; Alvarez, S.; Rodriguez-Barrios, F.; Alvarez, R.; Khanwalkar, H.; Gronemeyer, H.; de Lera, A. R. Dual RXR Agonists and RAR Antagonists Based on the Stilbene Retinoid Scaffold. ACS Med. Chem. Lett., 2014, 5, 533-537.
191. Nakanishi, T.; Nishikawa, J.-i.; Hiromori, Y.; Yokoyama, H.; Koyanagi, M.; Takasuga, S.; Ishizaki, J.-I.; Watanabe, M.; Isa, S.-I.; Utoguchi, N.; Itoh, N.; Kohno, Y.; Nishihara, T.; Tanaka, K. Trialkyltin Compounds Bind Retinoid X Receptor to Alter Human Placental Endocrine Functions. Mol. Endocrinol., 2005, 19, 2502-2516.
192. le Maire, A.; Grimaldi, M.; Roecklin, D.; Dagnino, S.; Vivat-Hannah, V.; Balaguer, P.; Bourguet, W. Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. EMBO Rep., 2009, 10, 367-373.
193. Venhorst, J.; Nunez, S.; Terpstra, J. W.; Kruse, C. G. Assessment of Scaffold Hopping Efficiency by Use of Molecular Interaction Fingerprints. J. Med. Chem., 2008, 51, 3222-3229.
194. Dawson, M. I.; Hobbs, P. D.; Jong, L.; Xiao, D.; Chao, W.-r.; Pan, C.; Zhang, X.-k. sp2-bridged diaryl retinoids: Effects of bridgeregion substitution on retinoid X receptor (RXR) selectivity. Bioorg. Med. Chem. Lett., 2000, 10, 1307-1310.
195. Lu, J.; Dawson, M. I.; Hu, Q. Y.; Xia, Z.; Dambacher, J. D.; Ye, M.; Zhang, X.-K.; Li, E. The effect of antagonists on the conformational exchange of the retinoid X receptor a ligand-binding domain. Magn. Reson. Chem., 2009, 47, 1071-1080.
196. Kobayashi, T.; Furusawa, Y.; Yamada, S.; Akehi, M.; Takenaka, F.; Sasaki, T.; Akahoshi, A.; Hanada, T.; Matsuura, E.; Hirano, H.; Tai, A.; Kakuta, H. Positron Emission Tomography to Elucidate Pharmacokinetic Differences of Regioisomeric Retinoid X Receptor Agonists. ACS Med. Chem. Lett., 2015, 6, 334-338.
197. Yamauchi, T.; Waki, H.; Kamon, J.; Murakami, K.; Motojima, K.; Komeda, K.; Miki, H.; Kubota, N.; Terauchi, Y.; Tsuchida, A.; Tsuboyama-Kasaoka, N.; Yamauchi, N.; Ide, T.; Hori, W.; Kato, S.; Fukayama, M.; Akanuma, Y.; Ezaki, O.; Itai, A.; Nagai, R.; Kimura, S.; Tobe, K.; Kagechika, H.; Shudo, K.; Kadowaki, T. Inhibition of RXR and PPARg ameliorates diet-induced obesity and type 2 diabetes. J. Clin. Inv., 2001, 108, 1001-1013.
198. Forman, B. M. The Antidiabetic Agent LG100754 Sensitizes Cells to Low Concentrations of Peroxisome Proliferator-activated Receptor g Ligands. J. Biol. Chem., 2002, 277, 12503-12506.
199. Cesario, R. M.; Klausing, K.; Razzaghi, H.; Crombie, D.; Rungta, D.; Heyman, R. A.; Lala, D. S. The Rexinoid LG100754 Is a Novel RXR:PPARg Agonist and Decreases Glucose Levels in Vivo. Mol. Endocrinol., 2001, 15, 1360-1369.
200. Chuang, K.-H.; Lee, Y.-F.; Lin, W.-J.; Chu, C.-Y.; Altuwaijri, S.; Wan, Y.-J. Y.; Chang, C. 9-cis-Retinoic Acid Inhibits Androgen Receptor Activity through Activation of Retinoid X Receptor. Mol. Endocrinol., 2005, 19, 1200-1212.